Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner

Conclusions:
We find that chronic treatment with DPP-4 inhibitors reduced MI size, via the GLP-1 receptor-PKA pathway, in a glucose-dependent manner. Glucose-sensitive cardioprotection of endogenous GLP-1 in diabetic patients may in part explain why intensive control of serum glucose levels has been associated with increased cardiovascular risk.

Source: Cardiovascular Diabetology - October 22, 2013 Category: Cardiology Authors: Derek HausenloyHannah WhittingtonAbigail WynneShah BegumLouise TheodorouNiels RiksenMihaela MocanuDerek Yellon Source Type: research